Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Convertible Debt (2023 - 2026)

TransMedics has reported Convertible Debt over the past 3 years, most recently at $452.8 million for Q4 2025.

  • For Q4 2025, Convertible Debt rose 0.64% year-over-year to $452.8 million; the TTM value through Dec 2025 reached $452.8 million, up 0.64%, while the annual FY2025 figure was $452.8 million, 0.64% up from the prior year.
  • Convertible Debt for Q4 2025 was $452.8 million at TransMedics, roughly flat from $452.1 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $452.8 million in Q4 2025 and troughed at $445.8 million in Q2 2023.
  • A 3-year average of $449.3 million and a median of $449.2 million in 2024 define the central range for Convertible Debt.
  • Biggest five-year swings in Convertible Debt: rose 0.61% in 2024 and later rose 0.64% in 2025.
  • Year by year, Convertible Debt stood at $447.1 million in 2023, then rose by 0.63% to $449.9 million in 2024, then rose by 0.64% to $452.8 million in 2025.
  • Business Quant data shows Convertible Debt for TMDX at $452.8 million in Q4 2025, $452.1 million in Q3 2025, and $451.4 million in Q2 2025.